Ivor Elrifi & Tiziana Life Sciences

Ivor Elrifi: Ivor Elrifi, CEO of Tiziana Life Sciences, expressed satisfaction with the positive data and the company's intention to advance the program toward approval, highlighting the drug's potential as a new treatment paradigm.

Tiziana Life Sciences: Tiziana Life Sciences announced positive updated clinical data for its lead candidate, intranasal foralumab, in patients with non-active Secondary Progressive Multiple Sclerosis, which could significantly advance its drug development program and potential market position.

Ivor Elrifi: Ivor Elrifi, CEO of Tiziana Life Sciences, expressed enthusiasm for reaching this milestone, highlighting the company's strong execution and the potential of the novel intranasal approach.

Tiziana Life Sciences: Tiziana Life Sciences is the biotechnology company developing intranasal foralumab and is conducting the INFORM-MS Phase 2a clinical trial. The successful dosing of the last patient is a significant milestone for the company, potentially leading to positive future clinical outcomes and increased investor confidence.

Ivor Elrifi: Ivor Elrifi, CEO of Tiziana Life Sciences, expressed enthusiasm for the preclinical data, reinforcing the company's positive outlook.

Tiziana Life Sciences: Tiziana Life Sciences announced positive preclinical data for its lead candidate, intranasal foralumab, showing its potential to treat Long COVID neuroinflammation and cognitive dysfunction. This positive data could significantly boost the company's stock price and future prospects.